Our passion for immuno-oncology is relentless

NewLink Genetics is a biopharmaceutical company focused on discovering, developing, and commercializing novel immuno-oncology products to improve the lives of patients with cancer.

Founded more than 15 years ago, NewLink Genetics continues to be at the forefront in immuno-oncology treatments led by a diverse group of industry professionals and physician-scientists. Personal cancer stories inspire our relentless research and development in advancing treatments. Our mission is to change the cancer treatment paradigm and make a difference in patient lives every day.


Charles J. Link, Jr, MD
Cofounder, Chairman, Chief Executive Officer, Chief Scientific Officer

Nicholas N. Vahanian, MD
Cofounder, President

Lisa DeLuca, PhD
Vice President, Regulatory Affairs

John B. Henneman III
Executive Vice President, Chief Financial Officer

Eugene P. Kennedy, MD
Chief Medical Officer

Carl Langren
Vice President, Finance

Mario Mautino, PhD
Senior Vice President, Drug Discovery, Intellectual Property Officer

Gabriela R. Rossi, PhD
Vice President, Biologics Development

Brian Wiley
Chief Commercial Officer